| Micro-channel |
 |
|
|
|
|
|
| |
| The first one! Fosun's medical device company is going public |
| |
| Author：中國銘鉉 企劃部 Release Time：2017-9-7 10:55:34 Number Browse：961 |
| |
The medical network September 7, "complex galaxy" or will be another public company.
Fosun international and fosun pharmaceutical's board announced that SISRAM MEDICAL LTD, a controlling subsidiary, had been disassembled and listed on the main board of the Hong Kong stock exchange on September 5.
According to the prospectus, Sisram intends to issue 110 million shares (assuming the overallotment has not been exercised), 90% of which are international sales, 10% for Hong Kong and 15% for the overallotment. Priced at hk $8.88 to hk $12.35, it is expected to be listed on September 19, with a market value of about hk $3.9 billion to hk $5.1 billion.
With the expert inside course of study to the "daily economic news" reporter said, domestic high-end medical beauty equipment brand is less, fosun pharma buys Alma Lasers (Sisram main assets) and now choose split listing is the right choice.
It is expected to be listed on September 19
Sisram for fosun medicine in Israel's subsidiary, is "the world's leading supplier of energy source medical cosmetology instrument", its main assets as a subsidiary of Alma Lasers (fly). The company's product line includes post-natal repair, anti-aging, depilation, skin treatment, and pigmentation treatment in five areas and was acquired by Sisram in 2013. According to the Medical Insight report, Sisram is now the largest provider of energy source Medical beauty equipment in the domestic market.
Fosun medicine revealed on July 15, 2016, suggested Sisram stake sale scale is not less than the expansion of 25% of the total equity, including the new shares issued by Sisram and may be composed of existing shareholders to sell shares, suggested after listed, Sisram continue to fosun medicine affiliated company.
According to the prospectus, Sisram is expected to be listed on September 19. Its global sale will be the size of approximately hk $976.8 million to about hk $1.3585 billion (assuming an overallotment option is not exercised), and approximately hk $1.1233 billion to about hk $1.5623 billion (assuming an overallotment option that number);
Sisram after issuance of market value of about hk $3.907 billion to about hk $4.986 billion (assuming an overallotment option is not exercised), and approximately hk $4.0537 billion to about hk $5.19 billion (assuming an overallotment option that number). Fosun pharmaceuticals will hold about 51.05% of Sisram shares (assuming the minimum selling price and the overallotment are informed).
Sisram2014, 2015 and 31 December 2016, the total revenue of $101.3 million, respectively, $110.4 million and $118.2 million, reported a profit this year to $6.7 million, $8.6 million and $8.5 million respectively, the main products include noninvasive medical hairdressing, minimally invasive medical hairdressing, and other services.
As of December 31, 2016, Chinese distributors are the largest customers and distributors of Sisram, accounting for more than 20% of total revenue in 2016. Revenue from Chinese distributors accounted for 19.8%, 23.4% and 21.8% in the last three years.
Fosun medicine also warned in the announcement: it is not guaranteed that the proposed separation and listing will be conducted.
High-end medical devices market can be in period
In fact, fosun has proposed a separate listing of Sisram by 2018.
For the split Sisram listing, fosun medicine has previously told the media that the main purpose is to "provide financial security for its entire industrial chain with a well-run subsidiary; The fund is mainly used for technical research and new product development, market expansion and brand promotion.
On September 5, third party medical service system MaiSiKang Shi Lichen founder, to the "daily economic news" reporter said, fosun medicine on high-end medical beauty equipment do very successful, a few years ago to buy fly is very right choice, listed in Hong Kong after its brand exposure rate increases, will be good for later business development.
At the same time, the current domestic market is disorderly, the domestic has little strength in the production of high-end medical beauty equipment company, most of the imported products, therefore, fly, product at present in domestic is also relatively easy to do.
Shi also said that in recent years, the domestic medicine market has been released quickly. According to a report from the international society of aesthetic plastic surgery, China's average annual medical treatment of 1,000 people in 2015 is about 1.5 times, compared with 12 times in the United States and 20 times in South Korea.
In 2015, when the value of medical products exceeded 500 billion yuan, the value of Chinese medical products would grow by 15.5% and 800 billion yuan in 2018. According to the Medical Insight report, direct sales revenue for the global energy source Medical cosmetology appliance market will increase from about $2.7 billion in 2016 to $4.4 billion in 2021, with annual compound growth of 10.4%.
|
| |
Previous article：Four Chinese traditional Chinese medicine products have skyrocketed to the market
Next article：Pharmacies conduct non - drug sales market analysis
|
| |
|
|
